Skip to main content

Merck s Bennett Shapiro Joins Elixir Board; Paradigm Gets Computational Systems Biology Director from Morphochem; Rescentris Appoints Four Executives

NEW YORK, April 16 - Bennett Shapiro of Merck has been appointed to the board of Elixir Pharmaceuticals, a Boston-area genomics-based drug discovery company, Elixir said today.

 

Shapiro currently serves as executive vice president of worldwide licensing and external research at Merck.   He has been at Merck since 1990, when he joined as executive vice president of basic research. Previously, he served as professor and chairman in the department of biochemistry at the University of Washington.

 


 

Brian Bullard has been appointed senior director of computational systems biology at Paradigm Genetics, the company said April 15. The company also appointed Michael Liebman, director of biomedical informatics at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, to its scientific advisory board.

 

Bullard comes to Paradigm from Morphochem, where he integrated the companies cheminformatics database and its genomics initiative, and initiated statistical-based data acceptance methods. He previously served as vice president and chief information officer at AxCell Biosciences, which is a subsidiary of Cytogen.

 

Liebman has moved to academia from pharma, most recently serving as global head of computational genetics at Roche Biosciences, and previously as director of biomedical informatics and pharmacogenomics at Wyeth-Ayerst. He also has worked at Vysis as director of bioinformatics.

 


 

Rescentris has appointed four new executives, the company said April 10. Eldred Ribiero is director of software development; Charles Guo is director of biomedical informatics; Wolfgang Rumpf is director of product development; and Lorie Karnath is managing director, international and chairperson of the scientific advisory board.

 

All three come to Rescentris, a Columbus, Ohio, life sciences informatics firm, from LabBook, where they all held similar positions. Rescentris was formed by former LabBook executives.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.